FOXO Transcription Factor Family in Cancer and Metastasis
Overview
Authors
Affiliations
Forkhead box O (FOXO) transcription factors regulate diverse biological processes, affecting development, metabolism, stem cell maintenance and longevity. They have also been increasingly recognised as tumour suppressors through their ability to regulate genes essential for cell proliferation, cell death, senescence, angiogenesis, cell migration and metastasis. Mechanistically, FOXO proteins serve as key connection points to allow diverse proliferative, nutrient and stress signals to converge and integrate with distinct gene networks to control cell fate, metabolism and cancer development. In consequence, deregulation of FOXO expression and function can promote genetic disorders, metabolic diseases, deregulated ageing and cancer. Metastasis is the process by which cancer cells spread from the primary tumour often via the bloodstream or the lymphatic system and is the major cause of cancer death. The regulation and deregulation of FOXO transcription factors occur predominantly at the post-transcriptional and post-translational levels mediated by regulatory non-coding RNAs, their interactions with other protein partners and co-factors and a combination of post-translational modifications (PTMs), including phosphorylation, acetylation, methylation and ubiquitination. This review discusses the role and regulation of FOXO proteins in tumour initiation and progression, with a particular emphasis on cancer metastasis. An understanding of how signalling networks integrate with the FOXO transcription factors to modulate their developmental, metabolic and tumour-suppressive functions in normal tissues and in cancer will offer a new perspective on tumorigenesis and metastasis, and open up therapeutic opportunities for malignant diseases.
Luperchio A, Salamango D Cells. 2025; 14(5).
PMID: 40072071 PMC: 11899004. DOI: 10.3390/cells14050342.
GSFM: A genome-scale functional module transformation to represent drug efficacy for drug discovery.
Tian S, Liao X, Cao W, Wu X, Chen Z, Lu J Acta Pharm Sin B. 2025; 15(1):133-150.
PMID: 40041913 PMC: 11873659. DOI: 10.1016/j.apsb.2024.08.017.
Targeting the PI3K/AKT/mTOR pathway in lung cancer: mechanisms and therapeutic targeting.
Qiang M, Chen Z, Liu H, Dong J, Gong K, Zhang X Front Pharmacol. 2025; 16:1516583.
PMID: 40041495 PMC: 11877449. DOI: 10.3389/fphar.2025.1516583.
Harnessing the FOXO-SIRT1 axis: insights into cellular stress, metabolism, and aging.
Gupta S, Afzal M, Agrawal N, Almalki W, Rana M, Gangola S Biogerontology. 2025; 26(2):65.
PMID: 40011269 DOI: 10.1007/s10522-025-10207-0.
Mahmoud E, Abdelhamid D, Mohammed A, Almarhoon Z, Brase S, Youssif B Pharmaceuticals (Basel). 2025; 18(2).
PMID: 40006087 PMC: 11859928. DOI: 10.3390/ph18020275.